What’s Next? Five Things To Look Out For In April
BSUFA Date Arrives For Alvotech; Japanese Price Revisions Await
Generics Bulletin previews the biggest events and changes for industry in the coming month.
You may also be interested in...
Viatris Looks To Call It A Day In US Januvia, Janumet Patent Saga
Viatris and Merck have disclosed plans to settle litigation currently pending before the US Court of Appeals for the Federal Circuit over the ANDA sponsor’s generic versions of its sitagliptin-containing medicines, Januvia (sitagliptin) and Janumet (sitagliptin/metformin).
Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients
Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.
Japan Price Revision: Mixture of Cuts And Increases Amid Supply Crisis
Japan’s annual drug reimbursement price revision for 2023 will cut approximately $2.3bn from national healthcare costs, and while several temporary price increases have been granted to cope with an ongoing supply crisis for some products, a system of one-off revisions for big sellers remains.